Brief: Alzinova receives approval to start first clinical study with ALZ-101 vaccine in patients with Alzheimer's disease
30/09/2021 14:57
Sept 30 (Reuters) - Alzinova AB ALZ.ST :
* ALZINOVA RECEIVES APPROVAL TO START FIRST CLINICAL STUDY
WITH
OLIGOMER-SPECIFIC ALZ-101 VACCINE IN PATIENTS WITH ALZHEIMER'S
DISEASE
Source text for Eikon: ID:nPn4TmSMVa
Further company coverage: ALZ.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzinova AB
See all newsBrief: Alzinova's Board Resolves On Directed Issue Of Units
Brief: Alzinova Announces Preliminary Outcome Of The Rights Issue
Brief: Alzinova Broadens Shareholder Base With New Investor
Brief: Alzinova Resolves On Rights Issue Of SEK 51 Mln
Brief: Alzinova Q2 Loss After Financial Items At SEK 5.4 Million